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Abstract
Aim To analyse the consumption of a number of medicines
with a known potential for increasing the risk of road traffic
accidents in the general population of Europe.
Methods Questionnaires were distributed through the
European Drug Utilization Research Group (EuroDURG)
and Post-Innovation Learning through Life-events of drugs
(PILLS) networks. A total of 30 countries (the current EU
Member States, Iceland, Norway and Switzerland) were
asked to supply data on the use of driving impairing
medicines for the period 2000–2005, aggregated at the level
of the active substance and presented in Defined Daily
Doses (DDDs) per 1000 inhabitants per day.
Results National utilization data were provided by 12 of the
30 countries. Based on these data, a considerable increase
in consumption was only seen for the antidepressants and
the selective serotonin reuptake inhibitors. A slight
increase, decrease or no increase was seen for the rest of
the drugs studied (i.e. opioids, antipsychotics, anxiolytics,
hypnotics and sedatives, drugs that are used in addictive
disorders and antihistamines). Limitations were encountered
when data on driving impairing medicines were compared
between countries (e.g. variation in the data sources and
providers,populationcoverage, inclusion of hospitaldata, use
of divergent ATC/DDD versions) and, therefore, a cross-
national comparison could not be performed.
Conclusions During the study period, trends within
countries showed slight to no increase in the consumption
of selected medicinal drug groups, with the exception of the
antidepressantsandtheselectiveserotoninreuptakeinhibitors:
they showed a remarkable increased use during the study
time-frame. Our results illustrate that it is still difficult to
perform a valid and comprehensive collection of drug
utilization data on driving impairing medicines. Therefore,
efforts to harmonize data collection techniques are required
and recommended.
Keywords Bias.Drivingimpairing medicines.
Drugutilization.Europeansurvey
Introduction
In the year 2000, more than 40,000 people in the European
Union (EU) were killed in road accidents and more than 1.7
million were injured [1]. An increasing proportion of these
road accidents can be attributed to the use of psychoactive
substances (i.e. alcohol, drugs and certain medicines), with
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over the years [2]. Consequently, a number of active steps
must be taken to gain better insight into this relevant societal
problem and introduce appropriate countermeasures.
In 2001, the European Commission set the ambitious goal
of halving the number of road deaths between 2003 and 2010
(EU Road Safety Target, White Paper) [3]. To meet this goal,
the Commission launched the 4-year DRiving Under the
Influence of Drugs, alcohol and medicines (DRUID) project
in October 2006 [4]. The objective of this integrated
European project is to provide scientific support to the EU
transport policy of reaching the 2010 road safety target.
However, critical information on the amount of driving
impairing medicinal products that are consumed by the
European population currently does not exist. Such informa-
tion is crucial as input for the future planning and successful
implementation of the DRUID project.
The aim of the study reported here was to describe the use
of some psychotropic medicines and some frequently used
medicines with Central Nervous System (CNS) side effects in
a non-hospitalized EU population between 2000 and 2005.
The consumption data were collected to detect trends that
illustrate an increased or decreased utilization of the most
relevant medicinal drug groups with known accident risk
potentials in the individual countries.
Methods
All current EU member states as well as other countries of
the wider European region (i.e. Iceland, Norway and
Switzerland) were invited to supply data on the use of
medicines of interest in their country. These countries were
approached through two international scientific networks—
the Post-Innovation Learning through Life-events of drugs
(PILLS) of Utrecht University, the Netherlands, and the
European Drug Utilization Research Group (EuroDURG)
[5]—or directly via public websites when possible (i.e.
Scandinavian countries and the Netherlands). The data were
requested for the time period 2000–2005; however, if data
were only available for part of the study period, responses
were still included in the study. Drug consumption
data were presented by the Anatomical Therapeutic
Chemical (ATC) Classification System, as recommended
by the World Health Organization (WHO) [6].
The included ATC subgroups (Table 1) cover the most
frequently used psychotropic medicines and medicines with
CNS side effects that are known to be of relevance for
traffic safety [7–12]. Glucose-lowering medicines and anti-
epileptic drugs, also known to be potentially impairing,
were excluded from the selection for this study because
extensive procedures are in place for the regulation of
driving while using these medicines [13].
Consumption was expressed in Defined Daily Doses
(DDDs)
1 per 1000 inhabitants per day or as the total
number of DDDs per year accompanied by the number of
inhabitants for the matching periods and region(s). The
DDD/1000 inhabitants per day measure was chosen since it
is a common unit of measurement tools used to present drug
utilization statistics, and it enables international comparisons
ofdruguseandevaluationsoftrendsindruguseovertime[6].
Consumption data on hospital care were not requested.
Information on the coverage of the data and the sources of
the data were requested (e.g. wholesaler data, reimbursement
data, pharmacy sale data, etc.) (Table 2).
The ACT code of a small number of the medicines of
interest for this study was changed during the study period
2000–2005 (Table 1). Levoceterizine remained within the
same therapeutic subgroup, while bupropion, levacetylme-
thadol and methadone were changed to a different therapeutic
subgroups [14]. In order to avoid bias, we requested the
consumption data on these three substances separately.
Lastly, the DDDs of four substances (bezitramide, fentanyl,
hydromorphone and oxycodone) changed during the time
frame of this retrospective study. We were unable to correct
for the impact of these DDD changes because specific
information was lacking.
Table 1 Selected groups of psychotropic medicines and medicines
with central nervous system side effects
Anatomical Therapeutic Chemical Classification System
N02A: Opioids (total group)
N05A: Antipsychotics
N05B: Anxiolytics
N05C: Hypnotics and sedatives
N06A: Antidepressants (total group)
N06AA: Non-selective monoamine reuptake inhibitors
N06AB: Selective serotonin reuptake inhibitors
N07B: Drugs used in addictive disorders (total group)
N07BA02: Bupropion
a
N07BC02: Methadone
a
N07BC03: Levacetylmethadol
a
R06A: Antihistamines for systemic use (total group)
R06AE: Piperazine derivatives
R06AX: Other antihistamines for systemic use
aThese substances changed therapeutic subgroups within the time
frame of this research question. The old ATC codes are N06AX12,
bupropion; N02AC06, levacethylmethadol; N02AC02, methadone.
1 The DDD is the assumed average maintenance dose per day for a
drug used for its main indication in adults. The DDD is a unit of
measurement and, therefore, it does not reflect precisely the
recommended or prescribed daily dose [6].
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Thirty countries were approached through the PILLS and
EuroDURG networks and public websites. Data from
13 countries were obtained (Bulgaria, Czech Republic,
Denmark, Finland, Germany, Hungary, Iceland, Norway,
Portugal, Serbia, Slovenia, Sweden and the Netherlands).
The response rate was 57%. Data from Czech Republic
were not included in this study as they did not meet the
study criteria (i.e. the medicinal products were aggregated
at a brand level, and consumption was expressed in number
of sold packages). Consequently, all data referred to
hereafter have been obtained from the remaining 12 EU
data providers.
Data providers and type of data
An overview of the specific data providers per country is
reported in Table 2. Data providers comprised national
agencies of medicines, national institutes of public health,
social insurance companies, ambulatory care data collected
by organizations of community pharmacies, ministries of
health, national health insurance companies and scientific
institutes of health insurance companies. Seven countries
(Bulgaria, Denmark, Finland, Germany, Norway, Sweden
and the Netherlands) provided the data as DDD/1000
inhabitants per day; the remaining countries (Hungary,
Iceland, Portugal, Serbia and Slovenia) provided the
number of DDDs together with the estimated covered
population.
Population coverage
Nine countries provided data covering 100% of the their
respectivepopulation,andthreecountries(Germany,Slovenia
and the Netherlands) could not provide consumption data that
covered 100% of their respective population.
Hospital data
Hospital consumption data were neither requested nor
included in this study. However, for some countries (Finland,
Iceland, Norway and Serbia), it was not possible to separate
the total data from ambulatory and hospital care data.
Medicinal drug utilization trends
The data on the use of psychotropic medicines and
medicines with CNS side effects are presented in Table 3.
This table gives an overview of the use of the selected drug
classes in 2005 and an indication of the consumption trends
in 2000–2005. It can be seen that the consumption of these
medicinal products varied across Europe. In general, a
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Eur J Clin Pharmacol (2009) 65:1139–1147 1143significative upward trend was only found for two of the
medicinal product classes of interest, namely the anti-
depressants and the Selective Serotonin Reuptake Inhib-
itors (SSRIs).
The consumption data showed an increase in the use of
antidepressants in 11 countries between 2000 and 2005. A
stable trend in antidepressant use was observed in Hungary.
There was a remarkable increase in the consumption of
SSRIs in six of the 12 countries that provided data, namely
Denmark, Finland, Iceland, Portugal, Slovenia and Sweden.
The remaining countries showed a slight increase in the use
of these active substances, with the exception of Hungary
where a stable trend was observed.
A slight increase, decrease or no increase at all in the use
of the drugs studied was found for most of the countries for
which data were obtained. Our analysis of German
consumption data revealed a considerable decrease in the
consumption of antihistamines.
Finally, some unusual patterns of methadone use were
observed in Denmark, Norway and Slovenia in the form of
an irregular consumption pattern. In general, there was a
rather large variation in the consumption of this medicine in
these countries over the period of interest.
Discussion
To the best of our knowledge, this is the first study carried
out on the general population of Europe that focuses on the
consumption of a number of frequently used medicinal
products with a known potential to increase the risk of road
traffic accidents. Our results indicate that the overall
utilization of psychotropic medicines and medicines with
CNS side effects has slightly increased, decreased or not
increased at all in Europe between 2000 and 2005.
Based on the national data that were made available to
us, only the consumption of antidepressants and SSRIs
showed a considerable increase during the study time
interval. The increased use of antidepressants is probably
associated to an increase in the consumption of SSRIs.
This trend was detected in all countries, with the
exception of Hungary, where a stable trend was registered
during the years of interest. In some countries, the
increase in the use of SSRIs may result from the current
clinical practice guidelines that recommend SSRIs as the
first-line treatment for panic and generalized anxiety
disorders, instead of benzodiazepines [15–17]. However,
it should be noted that our figures indicated that there had
been no significant decline in benzodiazepine use between
2000 and 2005.
Our data also indicate an irregular pattern of methadone
use in Denmark, Norway and Slovenia that deserves
attention. These trends may be explained either by the
primary utilization of this drug (i.e. maintenance anti-
addictive use in patients addicted to opioids) and the
consequent difficulties in obtaining valid consumption data
or by the various biases that could have potentially affected
the data collection procedures.
Contrary to expectations, a reduction in the use of
antihistamines was found in the German consumption data.
This finding may be explained by the implementation of
new legislation, the so-called GMG, in 2004 [18]. Part of
this legislation involved a change in the reimbursement
regulations for Over-The-Counter (OTC)-pharmaceuticals
and, for most indications, OTC products were no longer
reimbursed by the respective health insurance system, but
r a t h e rh a dt ob ep a i db yp a t i e n t st h e m s e l v e s .T h e
consumption of a number of OTC products may have been
slightly affected as a result.
An interesting result of our study is that, according to
our figures, the consumption of the medicines of interest in
the Scandinavian countries often appeared to be much
higher than that in the other European countries. Consid-
ering that these countries are well known for their rational
and conservative prescription practice [19] as well as the
fact that they have a long history and experience in data
collection [20], we suggest that the most probable reason
for this is that Scandinavian countries are able to deliver
more reliable and complete data on medicinal product
consumption than some of the other countries.
A number of significant limitations to this study need to
be considered. An important limitation may lie in the
incompleteness of data and in the non-availability of
information. In terms of the data collection process, the
availability of a cross-national collection system based on
the same data sources and data providers would provide
more reliable and complete data. However, such a system
does not exist, and, as a consequence, the differences in the
collection and reporting of data may have compromised the
validity of the drug utilization data.
Regarding the issue of incomplete data, it is interesting
to observe that, for example, our findings on anxiolytic and
antipsychotic drug use in Serbia do not support the findings
of a previous study that showed a considerably lower
consumption of these two drug classes [21]. This inconsis-
tency may be related to the use of different data sources and
providers. The same observations may also be valid for
another drug utilization study conducted in Portugal that
showed a lower use of hypnotics and sedatives than did our
study [22]. However, it is important to emphasize that the
discrepancies between the latter study and our study are less
remarkable. Moreover, it is relevant to note that our
findings on axiolytic use in Portugal are consistent with
those described by Furtado and Teixeira [22].
Another limitation may involve population coverage.
Nine countries were able to provide consumption data
1144 Eur J Clin Pharmacol (2009) 65:1139–1147that covered the whole population and three countries
(Germany, Slovenia and the Netherlands) could not.
However, even in data collection systems where 100% of
the population is supposed to be covered, census bias
cannot be completely ruled out. This bias may be due, for
example, to underdetection in the case of countries where
the reimbursement system does not cover the whole
population (in data collection systems based on reimburse-
ment data), slight variations in the exact number of insured
people (in data collection systems referring to consumption
data from insurance companies), missing or incorrect
information in the data source from which information on
drug use is obtained, among others.
Drug coverage may also have compromised our drug
utilization data. In countries where the drug of interest is
obtainable OTC, consumption may have been underesti-
mated, especially in the case of data collection systems
based onreimbursementdata. Underestimation may alsohave
occurredincountrieswheresomepsychotropicmedicinesand
medicines with CNS side effects are excluded from the
reimbursement lists, but the data collection system of these
countries is based on reimbursement data.
Another important point to be considered is the hospital
data. As stated above, hospital consumption data were not
intended to be included in this study. However, the drug
utilization data delivered by Finland, Iceland, Norway and
Serbia included hospital data. In Iceland, the hospital data
covered approximately 30% of the total consumption data;
in the other three countries, the percentage of coverage
could not be assessed. Consequently, drug consumption in
these countries may be overestimated.
Bias might also derive from the changes in the ATC or
DDD classification of the medicinal drug between 2000 and
2005. Although the data referring to the active substances
with a changed ATC code were requested separately, the
majority of the countries were not able to provide complete
data on the consumption of these substances. Therefore, we
were unable to correct for the impact of these changes and,
consequently, an underestimation of the use of these
medications cannot be completely ruled out. For example,
none of the 12 countries was able to provide data on the
consumption of levacetylmethadol. This could be due to the
fact that this active substance was not marketed or it was
not registered in the country (e.g. Hungary and Iceland) or
because of the withdrawal of Orlaam® (levacetylmethadol)
from the EU market in 2002 by the European Medicines
Agency (EMEA) [23]. The consumption of the four active
substances whose DDD changed during the study period
may also have been misclassified. No specific details on the
calculation of the number of DDDs were reported and,
therefore, we do not know whether the old or the new DDD
was used for this calculation. Other possible sources of bias
with respect to the ATC/DDD classification could be
associated with the use of different ATC/DDD versions,
different DDDs for combination products and the use of
unofficial or national DDDs [24].
In light of the above considerations, we can assert that,
despite highly developed administrative systems, it is still
difficult to collect valid and exhaustive drug utilization data
and, therefore, to perform a reliable cross-national compar-
ison in Europe. These findings are consistent with the study
carried out by Vander Stichele et al. [25], the rationale of
the EURO-MED-STAT project [26] as well as the findings
of other authors [24, 27–29].
Our results show that there are large differences in the
number of psychotropic drug prescriptions in the 12 EU
countries included in our study. Since the validity of the
data could not be assessed, it seems reasonable to state that
the above-mentioned variations may be due to the different
biases which hampered our consumption data. Consequently,
itisalsopossibletoconclude that, inthisstudy, patterns ofthe
use of the medicinal products of interest could only be
analysed on a national level.
Finally, it is important to highlight that this study did not
investigate the correlation between drug utilization patterns
and road traffic accidents trends within Europe between
2000 and 2005. However, a recent study of the use of
benzodiazepines (BDZs) and driving in Finland may
provide insight into this relationship [30]. BDZs are widely
used as anxiolytics and hypnotics, and they are also
commonly abused drugs [31]. Our findings show a stable
use of anxiolytics, hypnotics and sedatives in the period
2000–2005, but, on the other hand, they also show a
relatively high use of these drug classes, especially in
Scandinavian countries. The Finnish study found an
increased trend in driving under the influence of BDZs
during the period 2000–2005 [30]. Hence, it could be
hypothesized that the observed increase in the use of BDZs
may be correlated to the outcomes of our study. Another
recent study [32] found a correlation between the preva-
lence of BDZs among Norwegian drivers and the sales data
for these drugs. Similar outcomes also emerged from
another study [33] that found a relationship between the
number of prescriptions for BDZs in different Norwegian
provinces and the frequency of drivers testing positive for
BDZs from the same region. One of the issues that emerges
from these findings is that the consumption of a number of
prescribed drugs as well as of illicit drugs and alcohol
represent a real risk for road traffic safety. Consequently,
we can conclude that more research is needed to investigate
this association.
Conclusions
A slight increase in the use of psychotropic medicines and
medicines with CNS side effects has been observed in an
Eur J Clin Pharmacol (2009) 65:1139–1147 1145earlier study [34], and the results of our study partially
confirm this increase. However, since our study did not
focus on the association between the prevalence of
medicinal products and road traffic accidents, further
research is needed to gain a better understanding of the
scale of medicinal drug utilization in the driving population
and the relation between medicine use and driving. This
study also emphasizes that a trustworthy, methodological
approach is essential and necessary to ensure the validity,
reliability, and homogeneity of the data and enable cross-
national comparisons. Improvements should be made in
order to obtain better data, and there should be more
harmonization of the data collection techniques to establish
a reliable epidemiological database. Last, but not least,
international collaboration between different countries
would be most welcome and is highly recommended.
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